http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105315349-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2015-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105315349-B |
| titleOfInvention | A kind of the polypeptide NR16 and its transformation peptide of anti-angiogenesis |
| abstract | The invention belongs to biopharmaceutical technologies, and in particular to a kind of polypeptide NR16 and its transformation peptide [D Ala with blood vessel formation against function 1 ]AR17.NR16 contains 16 amino acid, molecular weight 1683.0, and amino acid sequence is：NLLMAASAAATWLPPR；Peptide [D Ala are transformed in NR16 1 ] AR17, including 17 amino acid, molecular weight 1754.1, specific amino acid sequence are：D‑ANLLMAASAAATWLPPR.There is certain similar degree with polypeptide A S16 structures in the present invention, equally show preferable tumor killing effect, can polypeptide A S16 be even preferably substituted as the supplement of polypeptide A S16, while also be that the development of the following new oncology pharmacy, exploitation provide new reference and possible. |
| priorityDate | 2015-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 113.